Caas Capital Management LP Terns Pharmaceuticals, Inc. Transaction History

Caas Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.62 - $10.18 $304,231 - $670,363	-65,851 Reduced 76.7%	20,000 $203,000
Q3 2022 Nov 14, 2022	SELL	$1.87 - $6.42 $21,806 - $74,863	-11,661 Reduced 11.96%	85,851 $213,000
Q2 2022 Aug 15, 2022	BUY	$1.5 - $3.0 $17,491 - $34,983	11,661 Added 13.58%	97,512 $242,000
Q3 2021 Nov 15, 2021	BUY	$7.22 - $13.46 $472,216 - $880,337	65,404 Added 319.87%	85,851 $895,000
Q2 2021 Aug 16, 2021	SELL	$12.26 - $22.0 $4.04 Million - $7.25 Million	-329,553 Reduced 94.16%	20,447 $251,000
Q1 2021 May 17, 2021	BUY	$17.13 - $27.25 $6 Million - $9.54 Million	350,000 New	350,000 $7.7 Million

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $216M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.